Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

STERIS plc STE

Healthcare — Medical Devices
S&P 500 Member Dividend Champion (5y) Cash Flow Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
9.87
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 3 — — — 1 — — 3 — 1 —
Insider Ownership
0.44%

Capital & Financial Ratios

Market Cap
20,280.00
Revenue
6,037.50
Net Income
808.10
Free Cash Flow
936.00
Net Debt
1,411.30
Current Ratio
1.91
Debt/Equity
0.26
P/E ratio
24.97
P/S ratio
3.31
P/B ratio
2.77
Past 5Y EPS Growth
5.92%
This Y EPS Growth
10.19%
Next Y EPS Growth
9.30%
Next 5Y EPS Growth
9.81%
in millions of $

Dividends

Payout Ratio
1.55
Annual Dividend Rate
2.08
Annual Dividend Yield
0.92%
total individual payouts
2029 ‡‡‡‡‡
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 2.43
—
—
—
2025 2.40
—
—
—
—
2024 2.18
—
—
—
—
2023 1.98
—
—
—
—
2022 1.80
—
—
—
—
2021 1.66
—
—
—
—
2020 1.54
—
—
—
—
2019 1.42
—
—
—
—
2018 1.30
—
—
—
—
2017 1.18
—
—
—
—
2016 1.06
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 207.02 171.70 439.60 482.30
Receivables 1,008.32 1,044.00 1,092.80 1,013.20
Inventory 674.54 581.30 631.80 712.10
Other 804.90 — — —
2,869.12 2,000.80 2,394.60 2,445.80
2024 2025 2026 Q'26
Payables 251.72 280.80 338.80 344.10
ST’ Debt 85.94 125.00 118.90 243.40
Other 64.01 616.40 687.40 695.70
931.13 1,022.20 1,145.00 1,283.30
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jun Sep Dec Mar Year
’26 1,492.70 — — —
—
’26 1,391.10 1,460.30 1,496.20 1,588.30
5,935.90
’25 1,279.50 1,328.90 1,370.60 1,480.50
5,459.50
’24 1,183.39 1,238.20 1,297.72 1,419.39
5,138.70
’23 1,156.49 1,200.52 1,215.99 963.26
4,536.27
’22 968.42 1,196.99 1,208.97 849.02
4,223.40
’21 668.93 756.13 808.92 873.53
3,107.52
in millions of $

Operating Cash Flow

Jun Sep Dec Mar Year
’26 367.10 — — —
—
’26 420.00 287.80 298.20 335.40
1,341.40
’25 303.70 250.80 332.80 260.80
1,148.10
’24 281.13 146.10 291.24 254.83
973.30
’23 231.75 103.82 205.58 215.80
756.95
’22 97.43 171.34 244.31 171.73
684.81
’21 134.12 161.95 205.71 187.86
689.64
in millions of $

Free Cash Flow

Jun Sep Dec Mar Year
’26 279.60 — — —
—
’26 326.50 201.20 209.90 245.30
982.90
’25 195.60 148.90 243.60 199.10
787.20
’24 214.53 70.16 172.32 163.39
620.40
’23 117.10 21.09 124.60 146.77
409.57
’22 41.25 94.54 164.51 98.69
398.99
’21 67.40 118.20 152.10 113.24
450.95
in millions of $

EPS

Jun Sep Dec Mar Year
’26 2.04 — — —
—
’26 1.79 1.94 1.96 2.24
7.93
’25 1.46 1.51 1.75 1.48
6.20
’24 1.25 1.16 1.42 (0.01)
3.81
’23 1.10 (3.15) 1.24 1.88
1.07
’22 (0.24) 0.69 1.42 0.52
2.48
’21 1.03 1.23 1.33 1.02
4.63

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 159.21 173.21 197.82 200.98 195.14 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 255.93 254.00 248.24 268.60 269.44 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16,422 17,100 18,179 17,787 17,937 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.26 0.27 0.28 0.31 0.33 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,223.40 4,536.27 5,138.70 5,459.50 5,935.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.59% 43.66% 43.16% 44.01% 44.25% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 366.80 680.27 702.80 796.20 1,047.30 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.69% 15.00% 13.68% 14.58% 17.64% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 242.87 105.81 380.10 616.10 785.10 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 619.77 560.26 570.00 476.20 486.50 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.30 45.50 52.01 55.37 60.45 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.50 1.07 3.83 6.24 7.97 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.02 7.59 9.85 11.64 13.66 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.93) (3.48) (3.57) (3.66) (3.65) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.09 4.11 6.28 7.98 10.01 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 67.10 61.05 63.92 67.10 73.29 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 97.54 99.71 98.80 98.60 98.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 99.91 175.49 57.71 36.38 27.78 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.58 4.20 4.25 4.09 3.66 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.60 3.13 3.46 3.38 3.02 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.23 4.84 4.83 4.44 3.91 ‡‡‡‡ ‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.97 53.57 40.03 30.77 23.61 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 684.81 756.95 973.30 1,148.10 1,341.40 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (285.82) (347.38) (352.90) (360.90) (358.50) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 398.99 409.57 620.40 787.20 982.90 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 956.78 1,149.60 1,938.00 978.60 1,249.60 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,088.36 3,078.66 3,206.10 2,043.70 1,931.70 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,740.04 2,870.30 2,999.08 1,872.00 1,492.10 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,544.64 6,087.17 6,315.35 6,615.80 7,197.20 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.71% 0.96% 3.46% 5.80% 7.49% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.22% 5.52% 5.61% 6.38% 7.92% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.67% 1.69% 6.10% 9.51% 11.33% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

STERIS plc (STE) has delivered impressive revenue growth, surging 129% from $2.24 billion in 2016 to $5.14 billion in 2024, fueled primarily by the $4.2 billion Fortive acquisition that boosted scale amid post-COVID sterilization demand. However, this expansion came at a cost: debt doubled to $3.09 billion, shares diluted by 14%, and gross margins stagnated around 40-44%, masking underlying efficiency struggles despite revenue per employee rising 77%. With the stock near yearly highs after a 230% run over eight years, insiders have offloaded $19.1 million in shares without a single buy, raising questions about sustainability.

Profitability tells a volatile tale, with net income plunging 51% in 2022 due to integration costs and rebounding unevenly, while ROE and ROIC seesawed from double-digits to single-digits low. Free cash flow improved to $787 million in 2024, but hefty capex and a debt load 120% above pre-pandemic levels strain the balance sheet, with EV/Sales at a premium 4.4x. Analysts forecast steady 6-10% revenue growth to $6.76 billion by 2028 and EPS to $10.07, but historical patterns tie gains to M&A rather than organic strength.

Trading at 31x forward earnings with modest 19% mean upside, STE’s premium valuation assumes perfection amid risks like supply chain disruptions, recession-hit elective procedures, and antitrust hurdles for future deals. This surface-level compounder hides eroding returns and a potential contrarian reversal—dive into the full analysis to uncover if the growth story holds or if a 20-30% pullback looms.

Read full commentary →

STERIS plc (STE) Latest News

News by impact score

Fine-tune

21 Aug

4 , 12:01 PM
STERIS plc commits $600 million to chemistry initiatives, with questions raised on whether its stock can deliver returns as the investment scales. The $600 million chemistry investment constitutes a major strategic move that could significantly alter STERIS's trajectory and investor sentiment.

9 Aug

3 transcript www.marketbeat.com, 4:03 AM
STERIS Q1 earnings call highlights financial results and operational updates. Q1 earnings details can shift short-term investor sentiment without major strategic shifts.

7 Aug

4 www.trains.com, 1:41 PM
North Carolina Railroad Co. and Norfolk Southern assist STERIS plc in landing a major medical manufacturing center in North Carolina. New manufacturing center expands STERIS production capacity and supports long-term operational growth.

6 Aug

4 www.manufacturingdive.com, 7:57 AM
STERIS plc (STE) will invest $600M to build a manufacturing hub in North Carolina. $600M manufacturing investment marks a major capacity expansion that can lift long-term output and growth.

4 www.sanfordherald.com, 7:00 AM
STERIS plc selects Sanford for a $600 million manufacturing campus. The $600 million manufacturing campus commitment represents a major capital expansion that can materially increase capacity and support long-term growth.

3 , 11:03 AM
STERIS Q1 earnings exceeded estimates while revenues missed targets, triggering a stock decline in aftermarket trading. Quarterly earnings and revenue results directly shape near-term financial performance perceptions and investor sentiment.

5 Aug

4 , 7:16 PM
STERIS plc commits $600 million to chemistries expansion, prompting assessment of whether the stock represents a bargain. $600 million chemistries expansion constitutes major strategic investment likely to alter company trajectory and investor sentiment.

4 , 8:45 AM
STERIS will invest $600 million to build a formulated chemistries manufacturing and distribution center of excellence in North Carolina. $600 million facility investment expands STERIS manufacturing capacity and supports long-term operational growth.

3 , 11:19 PM
STERIS plc commits to record investment in chemistries alongside a dividend increase, raising questions for investors on next steps. Record chemistries investment and dividend hike point to expanded operations and shareholder returns without transforming core trajectory.

3 , 6:30 PM
STERIS plc Q1 earnings key metrics detail revenue, earnings per share and segment results that reflect quarterly operational performance. Quarterly earnings metrics can shift near-term investor views on financial health without altering long-term strategy.

3 , 4:30 PM
STERIS plc (STE) released financial results for the first quarter of fiscal 2027. Quarterly earnings reports deliver performance metrics that can shift investor sentiment and near-term valuation.

19 Jun

3 , 6:04 AM
STERIS reported Q1 earnings and faces buy, sell, or hold analysis that weighs financial results against future outlook and market positioning. Post-Q1 earnings review may sway short-term investor views on STE without altering long-term fundamentals.

12 Jun

3 , 1:11 AM
STERIS missed Q4 estimates and issued 2027 outlook, with analysis now focused on what current valuation signals imply for the stock. Q4 miss and 2027 outlook directly shape near-term earnings expectations and valuation assessment.

15 May

4 www.marketbeat.com, 6:11 AM
STERIS plc released Q4 earnings call highlights covering financial results, strategic updates, and future outlook. Q4 earnings call highlights detail financial performance and guidance that significantly shape investor sentiment and company trajectory.

3 StockStory, 8:04 PM
STERIS plc posted Q1 results with margin expansion and service growth offsetting cost pressures. Q1 margin gains and service growth signal moderate positive effects on operational performance without major trajectory shifts.

13 May

3 StockStory, 2:52 AM
STERIS plc (STE) Q1 earnings preview outlines analyst expectations for revenue growth of 7-9%, adjusted EPS around $2.15-$2.25, and full-year guidance amid healthcare demand and acquisition integration. Q1 earnings expectations influence financial performance metrics and short-term investor sentiment without fundamentally altering long-term trajectory.

12 May

4 GuruFocus.com, 7:01 PM
STERIS plc reported record revenue growth in its Q4 2026 earnings call, highlighting strong performance and a positive strategic outlook. Record revenue growth and strategic outlook represent major positive developments likely to boost investor sentiment and alter STE's trajectory.

4 transcript www.fool.com, 12:02 PM
STERIS plc (STE) released its Q4 2026 earnings call transcript detailing financial results, operational updates, and future outlook. Q4 earnings transcripts reveal comprehensive financial performance, guidance, and strategic insights that significantly shape investor expectations and market trajectory.

4 app.moby.co, 8:30 AM
STERIS plc delivered its Q4 2026 earnings call, highlighting financial results, operational updates, and future outlook. Q4 earnings call summary discloses key financial metrics, guidance, and strategic updates that significantly shape investor sentiment and stock trajectory.

3 Zacks, 2:24 PM
STERIS plc (STE) reported Q4 earnings and revenues below expectations, resulting in a dip in aftermarket stock trading. Q4 earnings and revenue misses directly pressure near-term financial performance and market sentiment.

11 May

4 GlobeNewswire, 4:30 PM
STERIS plc announced financial results for fiscal 2026 fourth quarter and full year. Quarterly and annual financial results directly shape investor expectations, stock valuation, and future performance outlook.

3 Zacks, 6:05 PM
STERIS plc (STE) Q4 earnings and revenues missed analyst estimates. Q4 earnings and revenue misses highlight weaker financial results, moderately affecting short-term market sentiment and performance.

3 , 8:13 AM
STERIS plc (STE) appoints new diagnostics-focused director to board and announces dividend move, potentially shaping investor perceptions on strategic direction and financial health. Board addition of diagnostics expert and dividend adjustment moderately boost investor sentiment and signal strategic healthcare expansion.

5 May

3 StockStory, 3:08 AM
STERIS plc (STE) stock prompts buy, sell, or hold debate after Q4 earnings, evaluating financial results, guidance, and market outlook. Q4 earnings review influences STE's financial performance and investor sentiment moderately.

4 May

4 Zacks, 11:19 AM
STERIS plc (STE) Q4 earnings release approaches, with focus on potential stock movement amid analyst expectations for performance highlights. Upcoming Q4 earnings carry potential for major stock volatility through results, guidance, and market reactions.

20 Apr

4 , 10:21 AM
STERIS (NYSE:STE) delivered exceptional Q4 earnings in the surgical equipment and consumables diversified stocks sector, firing on all cylinders with strong performance across operations. Exceptional Q4 earnings highlight robust operational strength, likely driving significant positive shifts in market performance and investor sentiment.

8 Apr

3 , 10:49 AM
STERIS plc (STE) stock faces scrutiny on whether it's the right time to hold amid mixed financial results, growth challenges in healthcare segments, rising competition, and macroeconomic pressures, with analysts suggesting caution despite strong fundamentals. Debate on holding STE stock highlights moderate risks to investor sentiment and short-term performance from operational hurdles.

11 Feb

3 transcript StockStory, 12:35 AM
During STERIS plc's Q4 earnings call, analysts posed five intriguing questions that highlighted key areas of interest for the company. Topics included future growth strategies, product innovation, and market dynamics. The responses provided insights into STERIS's operational focus and potential challenges ahead, reflecting the company's positioning in the healthcare sector. The questions raised during the earnings call indicate moderate influences on STERIS's financial performance and competitive positioning.

9 Feb

4 Zacks, 9:15 AM
STERIS plc reported strong international revenue performance, highlighting growth in various regions and sectors. The company continues to expand its global footprint, driven by increased demand for its products and services. Key markets such as Europe and Asia contributed significantly to revenue growth, reflecting effective strategies and operational efficiencies. STERIS remains focused on innovation and customer satisfaction, positioning itself well for future opportunities in the healthcare and life sciences sectors. Strong international revenue growth and expansion strategies are likely to significantly impact future performance.

4 Simply Wall St., 4:09 AM
STERIC plc (STE) has reported stronger earnings and an increased dividend payout, which could significantly enhance investor confidence and market performance. The company's financial results indicate robust growth, positioning it favorably in the competitive landscape. Analysts suggest that these developments may lead to a re-evaluation of STERIS's stock, potentially attracting more investors and improving its market standing. Stronger earnings and a higher dividend payout are likely to significantly influence investor sentiment and the company's market trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us